Endothelin receptor antagonists for pulmonary arterial hypertension

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 3, 2021, Pages

  Liu, Chao ^a   Chen, Junmin ^b   Gao, Yanqiu ^a   Deng, Bao ^a   Liu, Kunshen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SITAXSENTAN; ANTIHYPERTENSIVE AGENT;

BORG DYSPNOEA SCORE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNOEA FATIGUE RATING; EVIDENCE BASED PRACTICE; HUMAN; LIVER FAILURE; LIVER TOXICITY; MORTALITY RATE; NEW YORK HEART ASSOCIATION CLASS; POPULATION RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SIX MINUTE WALK TEST; SYSTEMATIC REVIEW; META ANALYSIS; MORTALITY; STATISTICAL BIAS; WALK TEST;

ANTIHYPERTENSIVE AGENTS; BIAS; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WALK TEST;

EID: 85103079202     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004434.pub6     Document Type: Review

References (161)

1. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine 2015;373(9):834-44. x-wiley/crsRef/16156698 [DOI: 10.1056/NEJMoa1413687]
2. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-9. x-wiley/crsRef/3192571
3. US Food and Drug Administration Center for Drug Evaluation and Research. Letairis (Ambrisentan) Tablets: Medical Review(s). www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022081Orig1s039.pdf (accessed prior to 10 March 2020). x-wiley/crsRef/3192572
4. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-9. x-wiley/crsRef/3192574
5. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A. Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine 2002;346(12):896-903. x-wiley/crsRef/3192579
6. US Food and Drug Administration Center for Drug Evaluation and Research. Tracleer (Bosentan) Tablets: Medical Review(s). www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-290_Tracleer.cfm (accessed prior to 12 March 2020). x-wiley/crsRef/3192580
7. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. European Respiratory Journal 2004;24(3):353-9. x-wiley/crsRef/3192582
8. US Food and Drug Administration Center for Drug Evaluation and Research. Tracleer (Bosentan) Tablets: Medical Review(s). www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-290_Tracleer.cfm (accessed prior to 12 March 2020). x-wiley/crsRef/3192583
9. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114(1):48-54. x-wiley/crsRef/3192585
10. Badesch DB, Bodin F, Channick RN, Frost A, Rainisio M, Robbins IM, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research, Clinical and Experimental 2002;63(4):227-46. x-wiley/crsRef/3192587
11. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-23. x-wiley/crsRef/3192588
12. McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal 2015;46(2):405-13. x-wiley/crsRef/16156700 [DOI: 10.1183/13993003.02044-2014]
13. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371(9630):2093-100. x-wiley/crsRef/3192590
14. Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, et al. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Research & Therapy 2019;21:217. x-wiley/crsRef/16156702
15. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology 2003;41(8):1380-6. x-wiley/crsRef/3192592
16. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of macitentan in patients with Eisenmenger Syndrome. Circulation 2019;139(1):51-63. x-wiley/crsRef/16156704 [DOI: 10.1161/CIRCULATIONAHA.118.033575]
17. Krowka MJ, Cottreel E, De Groote P, Hoeper MM, Kim N, Martin N, et al. Efficacy and safety of macitentan in patients with portopulmonary hypertension: the randomized, placebo controlled portico trial. Hepatology. Conference 2018;Suppl 1:70A-71. x-wiley/crsRef/16156706 [DOI: 10.1002/hep.30256]
18. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine 2019;7:594-604. x-wiley/crsRef/16156707
19. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine 2005;171(11):1292-7. x-wiley/crsRef/3192594
20. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. New England Journal of Medicine 2013;369(9):809-18. x-wiley/crsRef/16156709 [DOI: 10.1056/NEJMoa1213917]
21. Barst RJ, Langleben D, Frost E, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 2004;169:441-7. x-wiley/crsRef/3192596
22. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (accessed 22 March 2008). x-wiley/crsRef/3192597
23. Therapeutic Goods Administration (TGA), Australia. Public summary documents by product: Thelin. www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sitaxentan-sodium-july07 (accessed 25 April 2008). x-wiley/crsRef/3192598
24. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology 2006;47(10):2049-56. x-wiley/crsRef/3192606
25. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.ema.europa.eu/en/medicines/human/EPAR/thelin (accessed prior to 22 March 2020). x-wiley/crsRef/3192607
26. Therapeutic Goods Administration (TGA), Australia. Public summary documents by product: Thelin. www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sitaxentan-sodium-july07 (accessed 25 April 2008). x-wiley/crsRef/3192608
27. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.ema.europa.eu/en/medicines/human/EPAR/thelin (accessed 22 March 2008). x-wiley/crsRef/3192618
28. Ahn LY, Kim SE, Yi S, Dingemanse J, Lim KS, Jang IJ, et al. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. American Journal of Cardiovascular Drugs 2014;14(5):377-85. x-wiley/crsRef/16156711
29. Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, et al. Exercise capacity and haemodynamics inpatients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology 2010;149(3):426-35. x-wiley/crsRef/3192624
30. Atsmon J, Dingemanse J, Shaikevich D, Volokhov I, Sidharta PN. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clinical Pharmacokinetics 2013;52(8):685-92. x-wiley/crsRef/16156713 [DOI: 10.1007/s40262-013-0063-8]
31. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation 2011;30(6):632-43. x-wiley/crsRef/3192626
32. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014;145(4):810-7. x-wiley/crsRef/16156715
33. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. Journal of Heart and Lung Transplantation 2007;26(1):63-9. x-wiley/crsRef/3192628
34. Bose N, Bena J, Trunick C, Petrich J, Bork DJ, Krishnan G, et al. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser doppler perfusion imaging. Arthritis and Rheumatism 2011;63(10 Suppl 1):S276-7. x-wiley/crsRef/16156717
35. Bruderer S, Hurst N, Kaufmann P, Dingemanse J. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology 2014;94(3-4):148-56. x-wiley/crsRef/16156719
36. NCT00070590. Efficacy and safety of oral bosentan in pulmonary fibrosis associated with scleroderma. clinicaltrials.gov/ct2/show/NCT00070590 (first received 8 October 2003). x-wiley/crsRef/3192632
37. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. European Journal of Clinical Pharmacology 2008;64(1):43-50. x-wiley/crsRef/16156721
38. Cardenas KPC, Velazquez JER, Escobar JJO, Chirinos J, Pendela M. Bioequivalence and tolerability of ambrisentan: a pharmacokinetic study in Mexican healthy male subjects. European Journal of Drug Metabolism and Pharmacokinetics 2020;45:611-8. x-wiley/crsRef/16156723
39. Chin KM, Sitbon O, Doelberg M, Gibbs JSR, Hoeper MM, Martin N, et al. Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (PAH): results of the randomized controlled triton study. American Journal of Respiratory and Critical Care Medicine 2020;201:A2928. x-wiley/crsRef/16156725
40. Coyne TC, Garces PC, Kramer W. No clinical interaction between sitaxsentan and sildenafil. In: American Thoracic Society 2005 International Conference, 2005 May 20-25; San Diego (CA). 2005. x-wiley/crsRef/3192636 [[A57] [Poster: K70]]
41. Danaietash P, Verweij P, Flamion B, Menard J, Bellet M. Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension. European Heart Journal 2019;40(Suppl 1):ehz747.0004. x-wiley/crsRef/16156727
42. Denault AY, Pearl RG, Michler RE, Rao V, Tsui SS, Seitelberger R, et al. Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial. Journal of Cardiothoracic and Vascular Anesthesia 2013;27(6):1212-7. x-wiley/crsRef/16156729
43. Dhaun N, Johnston NR, Goddard J, Webb DJ. Chronic selective endothelin a receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease. Hypertension 2011;58(2):e11-2. x-wiley/crsRef/16156731
44. Escribano-Subias P, Bendjenana H, Curtis PS, Lang I, Vonk Noordegraaf A. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary Circulation 2019;9(2):2045894019846433. x-wiley/crsRef/16156733 [DOI: 10.1177/2045894019846433]
45. Faoro V, Boldingh S, Moreels M, Martinez S, Lamotte M, Unger P, et al. Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. Chest 2009;135(5):1215-22. x-wiley/crsRef/16156735
46. Fatima N, Arshad S, Quddusi AI, Rehman A, Nadeem A, Iqbal I. Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension. Journal of Ayub Medical College, Abbottabad 2018;30(3):333-6. x-wiley/crsRef/16156737
47. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. Journal of Clinical Pharmacology 2008;48(8):926-34. x-wiley/crsRef/3192646
48. Galiè N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology 2005;46(3):529-35. x-wiley/crsRef/16704619
49. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-903. x-wiley/crsRef/16704621
50. Galiè N, Naeije R, Burgess G, Dilleen M. 3-year survival of patients treated with sitaxentan sodium (Thelin) for pulmonary arterial hypertension. European Heart Journal 2009;Abstract Supplement:262. x-wiley/crsRef/16704623
51. Galiè N, Badesch D, Fleming T, Simonneau G, Rubin L, Ewert R, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH): results from a phase II study. European Heart Journal 2010;3122(Suppl 1):22, 347. x-wiley/crsRef/3192654
52. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock A, Barst RJ, et al. Long term use of imatinib In patients with severe pulmonary arterial hypertension [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181:A2513. x-wiley/crsRef/3192656
53. Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jais X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine 2017;5(10):785-94. x-wiley/crsRef/16156739
54. Gillies HC, Wang X, Staehr P, Zack J. PAH therapy in HIV: lack of drug-drug interaction between ambrisentan and ritonavir. American Journal of Respiratory and Critical Care Medicine 2011;183:A5913. x-wiley/crsRef/3192658
55. Gillies H, Henig N, Pederson P, Shao L, Chien J, O'Riordan T, et al. A placebo-controlled study of ambrisentan in subjects with idiopathic pulmonary fibrosis (ARTEMIS-IPF). Life Sciences 2013;93(25-6):e59. x-wiley/crsRef/16156741
56. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101(25):2922-7. x-wiley/crsRef/3192660
57. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S, Arbor A. Efficacy and safety of sildenafil and atorvastatin added to bosentan as therapy for pulmonary arterial hypertension. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego (CA). 2005. x-wiley/crsRef/3192662 [[A57] [Poster: K18]]
58. Gotti E, Manes A, Palazzini M, Bernabe C, Bachetti C, Conficoni E, et al. A randomized open label study comparing first-line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension (CTEPH). European Heart Journal 2014;35:208. x-wiley/crsRef/16156743
59. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. Journal of Clinical Pharmacology 2010;50(7):829-34. x-wiley/crsRef/3192664
60. Grander W, Koller K, Steringer-Mascherbauer R, Ebner CH. Endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension. European Heart Journal 2014;35:692. x-wiley/crsRef/16156745
61. Grill S, Bruderer S, Sidharta PN, Antonova M, Globig S, Carlson J, et al. Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. British Journal of Clinical Pharmacology 2020;86(12):2424-34. x-wiley/crsRef/16156747
62. Gutierrez MM, Nicolas LB, Donazzolo Y, Dingemanse J. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation. International Journal of Clinical Pharmacology and Therapeutics 2013;51(6):529-36. x-wiley/crsRef/16156749
63. Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, et al. Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost. Respiratory Care 2017;62(4):489-96. x-wiley/crsRef/16156751 [DOI: 10.4187/respcare.05280]
64. Hill KD, Maharaj A, Thompson E, Li JS, Pearson E, Hornik C. A double blind, randomized, controlled pharmacokinetic and pharmacodynamics trial of ambrisentan after Fontan surgery. Circulation 2018;138:A14968. x-wiley/crsRef/16156753
65. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. European Respiratory Journal 2006;28(4):691-4. x-wiley/crsRef/3192666
66. Howard LS, Ghofrani HA, D'Armini AM, Fedullo P, Gesang S, Jais X, et al. Long-term safety, tolerability and efficacy of macitentan in patients with inoperable chronic thromboembolic pulmonary hypertension: the merit-1 study and its open-label extension merit-2. In: American Journal of Respiratory and Critical Care Medicine. Vol. 201. 2019:A6068. x-wiley/crsRef/16156755
67. Huez S, Faoro V, Moreels M, Bastin R, Retailleau K, Lamotte M, et al. Role of pulmonary hypertension and right ventricular dysfunction in aerobic exercise capacity limitation in normal volunteers at high altitude. Acta Cardiologica 2009;64(1):114. x-wiley/crsRef/3192668
68. Hurst N, Pellek M, Dingemanse J, Sidharta PN. Lack of pharmacokinetic interactions between macitentan and a combined oral contraceptive in healthy female subjects. American College of Clinical Pharmacology 2016;56(6):669-74. x-wiley/crsRef/16156757
69. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. European Heart Journal 2010;31(9):1124-31. x-wiley/crsRef/3192670
70. Jais X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Journal of the American College of Cardiology 2008;52(25):2127-34. x-wiley/crsRef/3192672
71. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? International Journal of Cardiology 2002;85(2-3):195-7. x-wiley/crsRef/3192674
72. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi-center randomized study. Cardiology 2008;109(4):273-80. x-wiley/crsRef/16156759
73. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Molecular Cancer 2010;9:69. x-wiley/crsRef/16156761
74. Keir G, Corte T, Parfitt L, Maher T, Marino P, Renzoni E, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia: a randomized, double-blind, placebo-controlled study. European Respiratory Journal 2013;42:1179. x-wiley/crsRef/16156763
75. Keir G, Corte T, Dimopoulos K, Gatzoulis M, Marino P, Renzoni E, et al. Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia [Abstract]. European Respiratory Journal 2014;44(Suppl 58):P2335. x-wiley/crsRef/16156765
76. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;177(1):75-81. x-wiley/crsRef/3192682
77. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346(8977):732-6. x-wiley/crsRef/16156767
78. Koller B, Steringer-Mascherbauer R, Ebner CH, Weber T, Ammer M, Eichinger J, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial). Heart, Lung and Circulation 2017;26(5):433-41. x-wiley/crsRef/16156769
79. Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis and Rheumatism 2004;50(12):3985-93. x-wiley/crsRef/3192686
80. Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clinical Science 2009;116(6):497-505. x-wiley/crsRef/3192688
81. Lindegger N, Sidharta PN, Reseski K, Dingemanse J. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects. Pulmonary Pharmacology and Therapeutics 2014;29(1):41-8. x-wiley/crsRef/16156771
82. Mazzanti G, Palazzini M, Leci E, Dardi F, Rinaldi A, D'Adamo A, et al. A randomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): long-term results. American Journal of Respiratory and Critical Care Medicine 2013;187:A3535. x-wiley/crsRef/16156773
83. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. Journal of Cardiovascular Pharmacology 2003;41(2):293-9. x-wiley/crsRef/3192690
84. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 2006;174(11):1257-63. x-wiley/crsRef/3192692
85. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology 2010;55(18):1915-22. x-wiley/crsRef/3192694
86. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114(14):1482-9. x-wiley/crsRef/3192696
87. Metersky M, Coyle T. The effect of the ET-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: a 17 week, double-blind, placebo-controlled crossover pilot study. Chest 2011;140(4):919A. x-wiley/crsRef/16156775
88. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, et al. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation 2006;114(13):1410-6. x-wiley/crsRef/3192698
89. Naeije R, Huez S, Lamotte M, Retailleau K, Neupane S, Abramowicz D, et al. Pulmonary artery pressure limits exercise capacity at high altitude. European Respiratory Journal 2010;36(5):1049-55. x-wiley/crsRef/16156777
90. Nakahara N, Wakamatsu A, Shimamura R, Nohda S, Miki S, Hirama T. Pharmacokinetics of ambrisentan, a novel drug for treatment of Pulmonary Arterial Hypertension (PAH), in Japanese subjects. Japanese Journal of Clinical Pharmacology and Therapeutics 2010;41(6):301-8. x-wiley/crsRef/3192702
91. NCT00077584. Efficacy and safety of oral bosentan on healing/prevention of digital (finger) ulcers in patients with scleroderma patients (RAPIDS-2) [A randomized, double-blind, placebo-controlled, multi-center study to assess the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis]. clinicaltrials.gov/ct2/show/NCT00077584 (first received 11 February 2004). x-wiley/crsRef/16704625
92. Okour M, Puri A, Chen G, Port K, Berni A, Khindri S, et al. A phase I study to show the relative bioavailability and bioequivalence of fixed-dose combinations of ambrisentan and tadalafil in healthy subjects. Clinical Therapeutics 2019;41:1110-27. x-wiley/crsRef/16156779
93. Oudiz RJ. Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension. Chest 2007;132(4):474a. x-wiley/crsRef/3192704
94. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54(21):1971-81. x-wiley/crsRef/3192706
95. Palazzini M, Mazzanti G, Gotti E, Bulatovic I, Manes A, Marinelli A, et al. A randomized open label study comparing bosentan to sildenafil first-line treatment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A3357. x-wiley/crsRef/16156781
96. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Annals of Internal Medicine 2013;158(9):641-9. x-wiley/crsRef/16156783
97. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal 2015;46(5):1370-7. x-wiley/crsRef/16156785
98. Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery 2010;139(1):85-91. x-wiley/crsRef/16156787
99. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. European Respiratory Journal 2006;27(3):578-84. x-wiley/crsRef/3192712
100. Schmetterer L, Dallinger S, Bobr B, Selenko N, Eichler H-G, Wolzt M. Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects. British Journal of Pharmacology 1998;124(5):930-4. x-wiley/crsRef/16156789
101. A receptor antagonist in men. Nitric Oxide 2001;5(4):370-6. x-wiley/crsRef/16156791
102. Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. European Journal of Heart Failure 2013;15(6):690-8. x-wiley/crsRef/16156793
103. Seheult RD, Ruh K, Foster GP, Anholm JD. Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Respiratory Physiology and Neurobiology 2009;165(2-3):123-30. x-wiley/crsRef/16156795
104. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis and Rheumatism 2010;62(7):2101-8. x-wiley/crsRef/16156797
105. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis and Rheumatism 2007;56(6):1985-93. x-wiley/crsRef/16156799
106. Shang XK, Li YP, Liu M, Zhou HM, Peng T, Deng XX, et al. Efficacy of endothelin receptor antagonist bosentan on the long-term prognosis in patients after Fontan operation. Zhonghua Xin Xue Guan Bing Za Zhi 2013;41(12):1025-8. x-wiley/crsRef/16156801
107. Shang XK, Lu R, Zhang X, Zhang CD, Xiao SN, Liu M, et al. Efficacy of bosentan in patients after fontan procedures: a double-blind, randomized controlled trial. Journal of Huazhong University of Science and Technology [Medical Sciences] 2016;36(4):534-40. x-wiley/crsRef/16156803
108. Sharma SK, Ajmani S, Sharma A, Singh S, Sinha S, Vishnubhatla S, et al. Comparison of efficacy of different treatment regimens in pulmonary hypertension secondary to lung disease and/or hypoxia [Abstract]. American Journal of Respiratory and Critical Care Medicine 2014;189:A1892. x-wiley/crsRef/16156805
109. Shenoy PD, Agarwal V. Tadalafil: a new role in Raynaud's phenomenon? International Journal of Clinical Rheumatology 2011;6(2):115-7. x-wiley/crsRef/3192718
110. Sidharta PN, Atsmon J, Dingemanse J. Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects. British Journal of Clinical Pharmacology 2010;70(6):930-1. x-wiley/crsRef/16156807
111. Sidharta PN, van Giersbergen PL, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. Journal of Clinical Pharmacology 2013;53(11):1131-8. x-wiley/crsRef/16704627
112. Sidharta PN, Lindegger N, Reseski K, Dingemanse J. Macitentan, a novel dual endothelin receptor antagonist, does not prolong the QT/QTC interval in a thorough QTC study in healthy subjects. Clinical Pharmacology and Therapeutics 2013;93(Suppl 1):S108-9. x-wiley/crsRef/16704629
113. Sidharta PN, Dietrich H, Dingemanse J. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Clinical Drug Investigation 2014;34(8):545-52. x-wiley/crsRef/16156813
114. Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, et al. Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH). American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A2515. x-wiley/crsRef/3192720
115. Simonneau G, Jing ZC, D'Armini AM, Fedullo P, Howard L, Jais X, et al. Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study. European Respiratory Journal 2017;50(Suppl 61):OA1984. x-wiley/crsRef/16156815
116. Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. Journal of Clinical Pharmacology 2008;48(12):1451-9. x-wiley/crsRef/3192722
117. Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. Journal of Pharmaceutical Sciences 2009;98(12):4962-74. x-wiley/crsRef/3192724
118. Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. British Journal of Clinical Pharmacology 2010;69(1):23-6. x-wiley/crsRef/3192726
119. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al. A randomised, controlled trial of bosentan in severe COPD. European Respiratory Journal 2008;32(3):619-28. x-wiley/crsRef/3192728
120. Surie S, Reesink HJ, Marcus JT, van der Plas MN, Kloek JJ, Vonk-Noordegraaf A, et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clinical Cardiology 2013;36(11):698-703. x-wiley/crsRef/16156817
121. Tanaka Y, Hino M, Gemma A. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis - an interim analysis of results from a prospective, single-center, randomized, parallel-group study. BMC Pulmonary Medicine 2017;17(1):200. x-wiley/crsRef/16156819 [DOI: 10.1186/s12890-017-0523-2]
122. Tanaka Y, Hino M, Aoyama J, Kosaihira S, Okano T, Seike M, et al. Interim report: long-term influence of bosentan on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with pulmonary hypertension secondary to COPD. In: Respirology. Vol. 24. 2019:239. x-wiley/crsRef/16156821
123. Vachiery J-L, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. European Respiratory Journal 2018;51(2):1880. x-wiley/crsRef/16156823
124. Van Der Zander K, Houben AJHM, Webb DJ, Udo E, Kietselaer B, Hofstra L, et al. Selective endothelin B receptor blockade does not influence BNP-induced natriuresis in man. Kidney International 2006;69(5):864-8. x-wiley/crsRef/16156825
125. Van Giersbergen PLM, Dingemanse J. Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. American College of Clinical Pharmacology 2005;45(1):42-7. x-wiley/crsRef/16156827
126. Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, et al. Longitudinal assessment of the effect of atrasentan on thoracic bioimpedance in diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Drugs in R&D 2017;17(3):441-8. x-wiley/crsRef/16156829
127. Worthington A, Collins N, Haddad R. Safety and feasibility of inhaled iloprost on exercise capacity in patients with pulmonary arterial hypertension. Heart Lung and Circulation 2010;19(2):1. x-wiley/crsRef/3192730
128. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. Journal of Clinical Pharmacology 2008;48(5):610-8. x-wiley/crsRef/3192732
129. Dwivedi P, Sharma SK, Dhir V, Rohit MK, Behera D, Jain S. AB0797 A randomised double blind placebo controlled trial to compare the efficacy of initial combination therapy vs monotherapy for pulmonary arterial hypertension in systemic sclerosis. Annals of the Rheumatic Diseases 2018;77(Suppl 2):1531. x-wiley/crsRef/16156831
130. Rinaldi A, Dardi F, Albini A, Gotti E, Monti E, Palazzini M, et al. Haemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. In: European Heart Journal. Vol. 39. 2018:P6341. x-wiley/crsRef/16156833
131. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
132. Badesch DB, the Aries Study Group. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology. Chest 2007;132(4):488-9.
133. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. New England Journal of Medicine 1996;334(5):296-302.
134. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Global Cardiology Science and Practice 2014;2014(2):62-78.
135. Veritas Health InnovationCovidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org.
136. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Annals of the Rheumatic Diseases 2006;65(10):1336-40.
137. Duo-Ji MM, Long ZW. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: a network meta-analysis. International Journal of Cardiology 2017;234:90-8.
138. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal 2015;46(4):903.
139. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 2 0 N ovmber 20 20. Hamilton (ON): McMaster University (developed by Evidence Prime).
140. Guignabert C, Tu L, Le HM, Ricard N, Sattler C, Seferian A, et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. European Respiratory Review 2013;22(130):543.
141. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.
142. Horinouchi T, Terada K, Higashi T, Miwa S. Endothelin receptor signaling: new insight into its regulatory mechanisms. Journal of Pharmacological Sciences 2013;123(2):85-101.
143. Khair RM, Nwaneri C, Damico RL, Kolb T, Hassoun PM, Mathai SC. The minimal important difference in Borg dyspnea score in pulmonary arterial hypertension. Annals of the American Thoracic Society 2016;13(6):842-9.
144. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and Expert Panel Report. CHEST 2019;155(3):565-86.
145. Madonna R, Cocco N, De Caterina R. Pathways and drugs in pulmonary arterial hypertension – focus on the role of endothelin receptor antagonists. Cardiovascular Drugs Therapy 2015;29(5):469-79.
146. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 2012;186(5):428-33.
147. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine 2000;161:487-92.
148. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
149. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. New England Journal of Medicine 1992;327(2):76-81.
150. Seibold J, Badesch D, Galiè N, Langleben D, Naeije R, Simonneau G, et al. Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). CHEST 2005;128(4):219S.
151. Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacological Research 2011;63(6):504-11.
152. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal 2019;53(1):1801913.
153. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. European Respiratory Journal 1998;12:265-70.
154. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Journal of the American College of Cardiology 2002;40(4):780-8.
155. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 2018;360:j5492.
156. Wang S, Yu M, Zheng X, Dong S. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Delivery 2018;25(1):1898-909.
157. Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research 2014;37(6):507-12.
158. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No: CD004434. [DOI: 10.1002/14651858.CD004434.pub2]
159. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No: CD004434. [DOI: 10.1002/14651858.CD004434.pub3]
160. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD004434. [DOI: 10.1002/14651858.CD004434.pub4]
161. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No: CD004434. [DOI: 10.1002/14651858.CD004434.pub5]